This month’s toughest USMLE Step 2 question to master
Getting ready for the United States Medical Licensing Examination® (USMLE®) Step 2 is no easy feat, but we’re sharing expert insights to help give you a leg up. Take a look at the exclusive scoop on this month’s most-missed USMLE Step 2 test prep question. Think you have what it takes to rise above your peers? Test your USMLE knowledge, and view an expert video explanation of the answer from Kaplan Medical.
Once you’ve got this question under your belt, be sure to test your knowledge with other posts in this series.
Ready. Set. Go.
This month’s question that stumped most students:
A 70-year-old woman pre...
Source: AMA Wire - June 28, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news
Allergan Announces FDA Approval of Supplemental New Drug Application (sNDA) for AVYCAZ(R) (ceftazidime and avibactam)
Label now includes Phase 3 clinical data evaluating the safety and efficacy of AVYCAZ (in combination with metronidazole) in patients with complicated intra-abdominal infections (cIAI)
DUBLIN, June 23, 2016 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, FDAAllergan, AVYCAZ, ceftazidime, avibactam, cIAI (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 23, 2016 Category: Pharmaceuticals Source Type: news
Complicated intra-abdominal infections: ceftolozane/tazobactam
This advice states that in a randomised controlled trial (RCT) in adults with complicated intra‑abdominal infections, intravenous ceftolozane/tazobactam plus metronidazole was found to be non‑inferior to intravenous meropenem plus saline (placebo) in terms of clinical cure rates 24–32 days after starting treatment. However, it is unclear whether the results apply to some populations; for example, people aged over 65 years, or those with renal impairment or who are at a higher risk of dying. Appendiceal perforation or abscess was the most common diagnosis in the study and less information is available on using ceftolo...
Source: Current Awareness Service for Health (CASH) - June 9, 2016 Category: Consumer Health News Source Type: news
Metronidazole-induced cerebellar syndrome
3.5 out of 5 stars
Metronidazole-Associated Encephalopathy. Farmakiotis D, Zeluff B. N Engl J Med 2016 Apr 14;374:1465
Full Text
Exposure to metronidazole (Flagyl) can precipitate a subacute cerebellar syndrome, typically manifested with dysarthria and ataxia, with or without cognitive impairment. This adverse effect is uncommon and little-appreciated. Although usually associated with prolonged exposure to the antibiotic for treatment of conditions such as abscesses of Clostridium difficile-associated diarrhea and occurring after total cumulative dose > 20 gm, the syndrome can occur after lower dose...
Source: The Poison Review - April 15, 2016 Category: Toxicology Authors: Leon Gussow Tags: Medical acute cerebellar syndrome encephalopathy metronidazole miri neurotoxicity Source Type: news
metronidazole gel, Metrogel, Metrocream, Metrolotion, Metrogel Vaginal, Vandazole, Noritate, Rosadan
Title: metronidazole gel, Metrogel, Metrocream, Metrolotion, Metrogel Vaginal, Vandazole, Noritate, RosadanCategory: MedicationsCreated: 1/29/2000 12:00:00 AMLast Editorial Review: 3/30/2016 12:00:00 AM (Source: MedicineNet Womens Health General)
Source: MedicineNet Womens Health General - March 30, 2016 Category: OBGYN Source Type: news
What is the Recurrence Risk for Clostridium difficile Infection?
Discussion
Clostridium difficile infection (CDI) is a common cause of nosocomial diarrhea.
Clostridium difficile is an obligate, anaerobic, gram-positive bacillus that is spore-forming and toxin producing. It is resistant to acid, heat, antibiotics and many antiseptic agents. Spores are acquired from the environment or by oral-fecal route. Once in the colon, the bacteria attach and proliferate making vegetative forms. Two main toxins are produced which disrupt the colonic integrity. Toxin A (TcdA) is an endotoxin that disrupts the mucosal cells. Toxin B (TcdB) is a cytotoxin that is 1000x more potent than TcdA and causes...
Source: PediatricEducation.org - March 28, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
FDA Accepts and Grants Priority Review for AVYCAZ(R) (ceftazidime and avibactam) Supplemental New Drug Application (sNDA)
Application Seeks to Expand AVYCAZ Label to Include Phase 3 Clinical Data for the Treatment of Complicated Intra-Abdominal Infections (cIAI), in Combination with Metronidazole
DUBLIN, Feb. 24, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan ... Biopharmaceuticals, FDAAllergan, AVYCAZ , intra-abdominal infection, ceftazidime, avibactam (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 24, 2016 Category: Pharmaceuticals Source Type: news
FDA Approves Antibacterial Combination Drug
The Food and Drug Administration has approved the antibacterial drug ceftazidime-avibactam (Avycaz) for complicated intra-abdominal infections in combination with metronidazole, and for complicated urinary tract infections including pyelonephritis in adults. (Source: Caring for the Ages)
Source: Caring for the Ages - August 1, 2015 Category: Health Management Authors: Patricia Wendling Source Type: news
Aurobindo gets USFDA nod for Metronidazole tablets
Aurobindo Pharma has received US health regulator's approval to manufacture and market Metronidazole Tablets, used to treat various kinds of infections, in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 1, 2015 Category: Pharmaceuticals Source Type: news
Ivermectin Cream vs Metronidazole Cream in Treating RosaceaIvermectin Cream vs Metronidazole Cream in Treating Rosacea
Metronidazole cream has been the standard treatment for the papulopustular lesions of rosacea. Is ivermectin cream a better alternative? The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 12, 2015 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Treatment reduces risk of recurrence of C. difficile infection
Among patients with Clostridium difficile infection (CDI) who recovered following standard treatment with the antibiotics metronidazole or vancomycin, oral administration of spores of a strain of C. difficile that does not produce toxins colonized the gastrointestinal tract and significantly reduced CDI recurrence, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2015 Category: Science Source Type: news
Treatment reduces risk of recurrence of C. difficile infection
(The JAMA Network Journals) Among patients with Clostridium difficile infection (CDI) who recovered following standard treatment with the antibiotics metronidazole or vancomycin, oral administration of spores of a strain of C. difficile that does not produce toxins colonized the gastrointestinal tract and significantly reduced CDI recurrence, according to a study in the May 5 issue of JAMA. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 5, 2015 Category: Infectious Diseases Source Type: news
Once-Daily Ivermectin Is a Safe Rosacea Treatment
Ivermectin cream (Soolantra) does a better job than metronidazole cream at treating the type of rosacea that causes bumps and pus pimples, according to a new study. (Source: WebMD Health)
Source: WebMD Health - April 1, 2015 Category: Consumer Health News Source Type: news
Once-Daily Ivermectin Safe and Effective Rosacea TreatmentOnce-Daily Ivermectin Safe and Effective Rosacea Treatment
Ivermectin is superior to metronidazole cream for the treatment of papulopustular rosacea, a parallel-group study has demonstrated. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 31, 2015 Category: Consumer Health News Tags: Dermatology News Source Type: news
